Convergent Therapeutics, Inc.

• 04/05/2023
• Series A
• $90,000,000

Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer.

Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

---

---